Applying the 2005 Canadian Hypertension Education Program recommendations: 2. Assessing and reducing global atherosclerotic risk among hypertensive patients

CMAJ. Canadian Medical Association Journal

Volumn 173, Issue 6, 2005, Pages 593-595

  Hemmelgarn, Brenda R ^a   Grover, Steven ^b   Feldman, Ross D ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CANADA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; EDUCATION PROGRAM; HUMAN; PROGNOSIS; RISK ASSESSMENT; SHORT SURVEY; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

EID: 25144463634     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.050185     Document Type: Short Survey

References (4)

1. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents. JAMA 2003;289:2534-44.
2. Hemmelgarn BR, McAlister FA, Myers MG, McKay DW, Bolli P, Abbott C, et al. The 2005 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: Part 1 - Blood pressure measurement, diagnosis, and assessment of risk. Can J Cardiol 2005; 21(8):645-56.
3. Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000;35:539-43.
4. Hansson L, Zanchetti A, Carruthers SG, Elmfeldt D, Julius S, Menard J, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-62.